Fixed 12-month treatment with Venclexta plus Gazyva significantly reduced risk of disease progression or death by 67% compared to a current standard-of-care Approval for expanded use of Venclexta offers more adults with chronic lymphocytic leukaemia a new treatment option - Roche today announced

Parties elect to refile Premerger Notification and Report Forms on or about 23 May 2019 to provide the government with additional time to complete its current review Roche and Spark Therapeutics, Inc.

In the dose-finding Part 1 of FIREFISH, infants with Type 1 spinal muscular atrophy survive and achieve key milestones beyond those expected in the natural history of the disease New data from the dose-finding Part 1 of SUNFISH reinforce risdiplam as a promising investigational therapy for people

New tests on cobas 6800/8800 systems provide clinicians information to help speed treatment and reduce the spread of infection Rising challenge of drug resistance compounds the tuberculosis global health crisis Mycobacteria test menu allows detection of tuberculosis, drug resistant tuberculosis a

Study results across 17 medicines reflect our commitment to personalised care with advances in targeted therapies, immunotherapy, and diagnostics, data and analytics New pivotal data on fixed-duration combination of Venclexta/Venclyxto plus Gazyva/Gazyvaro in previously untreated chronic lymphocy

The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The application was approved in just over 12 weeks under the US FDA's Real-Time Oncology Review pilot